{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-015230","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.290066+00:00","generated_at":"2026-06-06T02:14:50.607219+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adaptive Biotech Q4 revenue down 17% to $45.8M; net loss widens to $69.5M","bullets":["Full year 2023 revenue $170.3M (-8% YoY); MRD revenue $102.7M (+18%) offset by IM decline.","clonoSEQ test volume up 53% YoY to 56,496 tests delivered in 2023.","Net loss $225.3M in 2023 vs $200.4M in 2022; includes $25.4M lease impairment charge.","Adjusted EBITDA loss $116.4M in 2023 vs $121.6M loss in 2022.","2024 MRD revenue guidance $130-140M; total OpEx guided to $360-370M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-015230","json":"https://secwatch.observer/filing/0000950170-24-015230.json","markdown":"https://secwatch.observer/filing/0000950170-24-015230.md","text":"https://secwatch.observer/filing/0000950170-24-015230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/0000950170-24-015230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/adpt-20240214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:14:50.607219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c2bfcba39361d11aff6642e20297e5dd269cd12","claim":"Adaptive Biotechnologies Corp reported fourth quarter ended December 31, 2023 results: revenue $45.8 million, net income Net loss was $69.5 million.","evidence_excerpt":"Revenue was $45.8 million for the quarter ended December 31, 2023, representing a 17% decrease from the fourth quarter in the prior year. MRD revenue was $30.8 million for the quarter, representing a 9% increase from the fourth quarter in the prior year. Immune Medicine revenue was $15.0 million for the quarter, representing a 45% decrease from the fourth quarter in the prior year. Operating expenses, which include a $25.4 million lease impairment charge, were $116.9 million for the fourth quarter of 2023, compared to $94.4 million in the fourth quarter of the prior year, representing an increase of 24%. Excluding the impact of the lease impairment charge, operating expenses for the fourth quarter of 2023 decreased 3% compared to the fourth quarter of the prior year. Interest and other income, net was $4.6 million for the fourth quarter of 2023, compared to $2.6 million in the fourth quarter of the prior year. Interest expense from our revenue interest purchase agreement was $3.0 milli","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/0000950170-24-015230-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$45.8 million"},{"label":"Net income","value":"Net loss was $69.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a28e3210e5cb5c8cab3011b90d6fe847b08173f5","claim":"Adaptive Biotechnologies Corp reported fiscal year 2024 results: revenue between $130 million and $140 million. Guidance initiated.","evidence_excerpt":"2024 Financial Guidance Adaptive Biotechnologies expects full year revenue for the MRD business to be between $130 million and $140 million. No revenue guidance is provided for the Immune Medicine business. We expect full year operating expenses, including cost of revenue, to be between $360 million and $370 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/0000950170-24-015230-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024"},{"label":"Revenue","value":"between $130 million and $140 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"f19b2530875c274132fead4ddfe7899dffee70e5","claim":"Adaptive Biotechnologies Corp reported full year ended December 31, 2023 results: revenue $170.3 million, net income Net loss was $225.3 million.","evidence_excerpt":"Revenue was $170.3 million for the year ended December 31, 2023, representing an 8% decrease from the prior year. MRD revenue was $102.7 million in 2023, representing an 18% increase from the prior year. Immune Medicine revenue was $67.5 million in 2023, representing a 31% decrease from 2022. Operating expenses for 2023, which include a $25.4 million lease impairment charge, were $397.3 million, compared to $385.5 million for 2022, representing an increase of 3%. Excluding the impact of the lease impairment charge, operating expenses for 2023 decreased 4% compared to the prior year. Interest and other income, net was $15.5 million in 2023, compared to $4.1 million in 2022. Interest expense from our revenue interest purchase agreement was $13.8 million in 2023, compared to $4.2 million in 2022. Net loss was $225.3 million in 2023, compared to $200.4 million in 2022. Adjusted EBITDA (non-GAAP) was a loss of $116.4 million for 2023, compared to a loss of $121.6 million in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024015230/0000950170-24-015230-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Revenue","value":"$170.3 million"},{"label":"Net income","value":"Net loss was $225.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}